Petrenko, V., Sinturel, F., Riezman, H. & Dibner, C. Lipid metabolism around the body clocks. Prog. Lipid Res. 91, 101235 (2023).
Brown, E. M., Clardy, J. & Xavier, R. J. Gut microbiome lipid metabolism and its impact on host physiology. Cell Host Microbe 31, 173–186 (2023).
Xia, L. et al. The cancer metabolic reprogramming and immune response. Mol. Cancer 20, 28 (2021).
Zhivaki, D. & Kagan, J. C. Innate immune detection of lipid oxidation as a threat assessment strategy. Nat. Rev. Immunol. 22, 322–330 (2022).
Morigny, P., Boucher, J., Arner, P. & Langin, D. Lipid and glucose metabolism in white adipocytes: pathways, dysfunction and therapeutics. Nat. Rev. Endocrinol. 17, 276–295 (2021).
Kuo, A. & Hla, T. Regulation of cellular and systemic sphingolipid homeostasis. Nat. Rev. Mol. Cell Biol. 25, 802–821 (2024).
Solving the riddle of the role of Sphingolipids in cell signaling. J. Biol. Chem. 291, 11460–11461 (2016).
Kleuser, B. The enigma of sphingolipids in health and disease. Int. J. Mol. Sci. 19, 3126 (2018).
Olson, R. E. Discovery of the lipoproteins, their role in fat transport and their significance as risk factors. J. Nutr. 128, 439S–443S (1998).
Professor Tiedemann. West. J. Med. Surg. 2, 55 (1854).
Adorini, L. & Trauner, M. FXR agonists in NASH treatment. J. Hepatol. 79, 1317–1331 (2023).
Hokin, L. & Hokin, M. R. Effects of acetylcholine on the turnover of phosphoryl units in individual phospholipids of pancreas slices and brain cortex slices. 1955. Biochim Biophys. Acta 1000, 470–478 (1989).
Tsujita, Y. et al. Hypolipidemic effects in dogs of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Atherosclerosis 32, 307–313 (1979).
Hartel, J. C., Merz, N. & Grosch, S. How sphingolipids affect T cells in the resolution of inflammation. Front. Pharm. 13, 1002915 (2022).
Simons, K. & Toomre, D. Lipid rafts and signal transduction. Nat. Rev. Mol. Cell Biol. 1, 31–39 (2000).
Gutierrez, S., Svahn, S. L. & Johansson, M. E. Effects of omega-3 fatty acids on immune cells. Int. J. Mol. Sci. 20, 5028 (2019).
Han, X. & Gross, R. W. The foundations and development of lipidomics. J. Lipid Res. 63, 100164 (2022).
Jeromson, S., Gallagher, I. J., Galloway, S. D. & Hamilton, D. L. Omega-3 fatty acids and skeletal muscle health. Mar. Drugs 13, 6977–7004 (2015).
Avela, H. F. & Siren, H. Advances in lipidomics. Clin. Chim. Acta 510, 123–141 (2020).
Holcapek, M. New trends in lipidomics. Anal. Bioanal. Chem. 416, 5401–5402 (2024).
Wilfahrt, D. & Delgoffe, G. M. Metabolic waypoints during T cell differentiation. Nat. Immunol. 25, 206–217 (2024).
Collins, T. J. C. et al. The influence of metabolic disorders on adaptive immunity. Cell Mol. Immunol. 21, 1109–1119 (2024).
Martin-Perez, M., Urdiroz-Urricelqui, U., Bigas, C. & Benitah, S. A. The role of lipids in cancer progression and metastasis. Cell Metab. 34, 1675–1699 (2022).
Kanno, T., Nakajima, T., Miyako, K. & Endo, Y. Lipid metabolism in Th17 cell function. Pharm. Ther. 245, 108411 (2023).
Kennewick, K. T. & Bensinger, S. J. Decoding the crosstalk between mevalonate metabolism and T cell function. Immunol. Rev. 317, 71–94 (2023).
Deng, L., Kersten, S. & Stienstra, R. Triacylglycerol uptake and handling by macrophages: from fatty acids to lipoproteins. Prog. Lipid Res. 92, 101250 (2023).
Shao, N. et al. Targeting lipid metabolism of macrophages: a new strategy for tumor therapy. J. Adv. Res. 68, 99–114 (2025).
Jeon, Y. G., Kim, Y. Y., Lee, G. & Kim, J. B. Physiological and pathological roles of lipogenesis. Nat. Metab. 5, 735–759 (2023).
Dikalov, S., Panov, A. & Dikalova, A. Critical role of mitochondrial fatty acid metabolism in normal cell function and pathological conditions. Int. J. Mol. Sci. 25, 6498 (2024).
Wang, R., Liu, Z., Fan, Z. & Zhan, H. Lipid metabolism reprogramming of CD8(+) T cell and therapeutic implications in cancer. Cancer Lett. 567, 216267 (2023).
Liu, X. et al. Reprogramming lipid metabolism prevents effector T cell senescence and enhances tumor immunotherapy. Sci. Transl. Med. 13, eaaz6314 (2021).
Brennan, E., Kantharidis, P., Cooper, M. E. & Godson, C. Pro-resolving lipid mediators: regulators of inflammation, metabolism and kidney function. Nat. Rev. Nephrol. 17, 725–739 (2021).
Kraus, F. V. et al. Reduction of proinflammatory effector functions through remodeling of fatty acid metabolism in CD8+ T cells from rheumatoid arthritis patients. Arthritis Rheumatol. 75, 1098–1109 (2023).
Robinson, G., Pineda-Torra, I., Ciurtin, C. & Jury, E. C. Lipid metabolism in autoimmune rheumatic disease: implications for modern and conventional therapies. J. Clin. Investig. 132, e148552 (2022).
Lim, S. A., Su, W., Chapman, N. M. & Chi, H. Lipid metabolism in T cell signaling and function. Nat. Chem. Biol. 18, 470–481 (2022).
Kim, C. H. Complex regulatory effects of gut microbial short-chain fatty acids on immune tolerance and autoimmunity. Cell Mol. Immunol. 20, 341–350 (2023).
Tan, J. K., Macia, L. & Mackay, C. R. Dietary fiber and SCFAs in the regulation of mucosal immunity. J. Allergy Clin. Immunol. 151, 361–370 (2023).
Haskey, N. et al. A Mediterranean diet pattern improves intestinal inflammation concomitant with reshaping of the bacteriome in ulcerative colitis: a randomised controlled trial. J. Crohns Colitis 17, 1569–1578 (2023).
Wastyk, H. C. et al. Gut-microbiota-targeted diets modulate human immune status. Cell 184, 4137–4153.e4114 (2021).
Desai, M. S. et al. A dietary fiber-deprived gut microbiota degrades the colonic mucus barrier and enhances pathogen susceptibility. Cell 167, 1339–1353.e1321 (2016).
Corbin, K. D. et al. Host-diet-gut microbiome interactions influence human energy balance: a randomized clinical trial. Nat. Commun. 14, 3161 (2023).
Mann, E. R., Lam, Y. K. & Uhlig, H. H. Short-chain fatty acids: linking diet, the microbiome and immunity. Nat. Rev. Immunol. 24, 577–595 (2024).
Gonzalez-Bosch, C., Boorman, E., Zunszain, P. A. & Mann, G. E. Short-chain fatty acids as modulators of redox signaling in health and disease. Redox Biol. 47, 102165 (2021).
Kim, M., Qie, Y., Park, J. & Kim, C. H. Gut microbial metabolites fuel host antibody responses. Cell Host Microbe 20, 202–214 (2016).
Daien, C. I. et al. Gut-derived acetate promotes B10 cells with antiinflammatory effects. JCI Insight 6, e144156 (2021).
Hu, M. et al. Decreased maternal serum acetate and impaired fetal thymic and regulatory T cell development in preeclampsia. Nat. Commun. 10, 3031 (2019).
Wu, H. et al. Gut microbial metabolites induce donor-specific tolerance of kidney allografts through induction of T regulatory cells by short-chain fatty acids. J. Am. Soc. Nephrol. 31, 1445–1461 (2020).
Duscha, A. et al. Propionic acid shapes the multiple sclerosis disease course by an immunomodulatory mechanism. Cell 180, 1067–1080.e1016 (2020).
Park, J. et al. Short-chain fatty acids induce both effector and regulatory T cells by suppression of histone deacetylases and regulation of the mTOR-S6K pathway. Mucosal Immunol. 8, 80–93 (2015).
Sarkar, A. et al. Butyrate limits inflammatory macrophage niche in NASH. Cell Death Dis. 14, 332 (2023).
Liu, H. et al. The metabolite butyrate produced by gut microbiota inhibits cachexia-associated skeletal muscle atrophy by regulating intestinal barrier function and macrophage polarization. Int. Immunopharmacol. 124, 111001 (2023).
Scott, N. A. et al. Antibiotics induce sustained dysregulation of intestinal T cell immunity by perturbing macrophage homeostasis. Sci. Transl. Med. 10, eaao4755 (2018).
Huang, C. et al. The effect of short-chain fatty acids on M2 macrophages polarization in vitro and in vivo. Clin. Exp. Immunol. 207, 53–64 (2022).
Wang, G. et al. Ginsenoside Rg3 enriches SCFA-producing commensal bacteria to confer protection against enteric viral infection via the cGAS-STING-type I IFN axis. ISME J. 17, 2426–2440 (2023).
Poli, V. & Zanoni, I. Neutrophil intrinsic and extrinsic regulation of NETosis in health and disease. Trends Microbiol. 31, 280–293 (2023).
Wang, H. et al. Neutrophil extracellular traps in homeostasis and disease. Signal Transduct. Target Ther. 9, 235 (2024).
Adrover, J. M. et al. NETworking with cancer: the bidirectional interplay between cancer and neutrophil extracellular traps. Cancer Cell 41, 505–526 (2023).
Wigerblad, G. & Kaplan, M. J. Neutrophil extracellular traps in systemic autoimmune and autoinflammatory diseases. Nat. Rev. Immunol. 23, 274–288 (2023).
Lv, G. et al. Effects of Hormone, NEFA and SCFA on the migration of neutrophils and the formation of neutrophil extracellular traps in dairy cows. Animals12, 1190 (2022).
Carretta, M. D. et al. Butyric acid stimulates bovine neutrophil functions and potentiates the effect of platelet-activating factor. Vet. Immunol. Immunopathol. 176, 18–27 (2016).
Vinolo, M. A. et al. Short-chain fatty acids stimulate the migration of neutrophils to inflammatory sites. Clin. Sci.117, 331–338 (2009).
Inamoto, T. et al. Short-chain fatty acids stimulate dendrite elongation in dendritic cells by inhibiting histone deacetylase. FEBS J. 290, 5794–5810 (2023).
Folkerts, J. et al. Butyrate inhibits human mast cell activation via epigenetic regulation of FcepsilonRI-mediated signaling. Allergy 75, 1966–1978 (2020).
Nagata, K. et al. Butyrate, valerate, and niacin ameliorate anaphylaxis by suppressing IgE-dependent mast cell activation: roles of GPR109A, PGE2, and epigenetic regulation. J. Immunol. 212, 771–784 (2024).
Shrivastava, M., Roy, D. & Chaba, R. Long-chain fatty acids as nutrients for Gram-negative bacteria: stress, proliferation, and virulence. Curr. Opin. Microbiol. 85, 102609 (2025).
Brix, S. et al. CD4(+) T-cell activation is differentially modulated by bacteria-primed dendritic cells, but is generally down-regulated by n-3 polyunsaturated fatty acids. Immunology 129, 338–350 (2010).
Borja-Magno, A. et al. Differential effects of high dose omega-3 fatty acids on metabolism and inflammation in patients with obesity: eicosapentaenoic and docosahexaenoic acid supplementation. Front. Nutr. 10, 1156995 (2023).
Cucchi, D. et al. Omega-3 polyunsaturated fatty acids impinge on CD4+ T cell motility and adipose tissue distribution via direct and lipid mediator-dependent effects. Cardiovasc. Res. 116, 1006–1020 (2020).
Ye, Z. et al. Arachidonic acid-regulated calcium signaling in T cells from patients with rheumatoid arthritis promotes synovial inflammation. Nat. Commun. 12, 907 (2021).
Weatherill, A. R. et al. Saturated and polyunsaturated fatty acids reciprocally modulate dendritic cell functions mediated through TLR4. J. Immunol. 174, 5390–5397 (2005).
van den Elsen, L. W. et al. DHA-rich tuna oil effectively suppresses allergic symptoms in mice allergic to whey or peanut. J. Nutr. 144, 1970–1976 (2014).
van den Elsen, L. W. et al. CD25+ regulatory T cells transfer n-3 long-chain polyunsaturated fatty acids-induced tolerance in mice allergic to cow’s milk protein. Allergy 68, 1562–1570 (2013).
Harbige, L. S. & Fisher, B. A. Dietary fatty acid modulation of mucosally-induced tolerogenic immune responses. Proc. Nutr. Soc. 60, 449–456 (2001).
Suzuki, N. et al. Association between polyunsaturated fatty acid and reactive oxygen species production of neutrophils in the general population. Nutrients 12, 3222 (2020).
Sun, X. et al. The blood immune cell count, immunoglobulin, inflammatory factor, and milk trace element in transition cows and calves were altered by increasing the dietary n-3 or n-6 polyunsaturated fatty acid levels. Front Immunol. 13, 897660 (2022).
Draper, E. et al. Conjugated linoleic acid suppresses dendritic cell activation and subsequent Th17 responses. J. Nutr. Biochem. 25, 741–749 (2014).
Munson, P. V. et al. Polyunsaturated fatty acid-bound alpha-fetoprotein promotes immune suppression by altering human dendritic cell metabolism. Cancer Res. 83, 1543–1557 (2023).
Wang, X., Ma, D. W., Kang, J. X. & Kulka, M. n-3 Polyunsaturated fatty acids inhibit Fc epsilon receptor I-mediated mast cell activation. J. Nutr. Biochem. 26, 1580–1588 (2015).
Pompura, S. L. et al. Oleic acid restores suppressive defects in tissue-resident FOXP3 Tregs from patients with multiple sclerosis. J. Clin. Investig. 131, e138519 (2021).
Lai, Y. et al. Dietary elaidic acid boosts tumoral antigen presentation and cancer immunity via ACSL5. Cell Metab. 36, 822–838 e828 (2024).
Haghikia, A. et al. Dietary fatty acids directly impact central nervous system autoimmunity via the small intestine. Immunity 43, 817–829 (2015).
Hammer, A. et al. Impact of combined sodium chloride and saturated long-chain fatty acid challenge on the differentiation of T helper cells in neuroinflammation. J. Neuroinflamm. 14, 184 (2017).
Kim, D. H. et al. Oleate protects macrophages from palmitate-induced apoptosis through the downregulation of CD36 expression. Biochem. Biophys. Res. Commun. 488, 477–482 (2017).
Wang, Y. et al. Saturated palmitic acid induces myocardial inflammatory injuries through direct binding to TLR4 accessory protein MD2. Nat. Commun. 8, 13997 (2017).
Karasawa, T. et al. Saturated fatty acids undergo intracellular crystallization and activate the NLRP3 inflammasome in macrophages. Arterioscler Thromb. Vasc. Biol. 38, 744–756 (2018).
Korbecki, J. & Bajdak-Rusinek, K. The effect of palmitic acid on inflammatory response in macrophages: an overview of molecular mechanisms. Inflamm. Res. 68, 915–932 (2019).
Youk, H. et al. Nlrp3, Csf3, and Edn1 in macrophage response to saturated fatty acids and modified low-density lipoprotein. Korean Circ. J. 51, 68–80 (2021).
Tall, A. R. & Yvan-Charvet, L. Cholesterol, inflammation and innate immunity. Nat. Rev. Immunol. 15, 104–116 (2015).
Xu, D. et al. Cholesterol sulfate alleviates ulcerative colitis by promoting cholesterol biosynthesis in colonic epithelial cells. Nat. Commun. 13, 4428 (2022).
Hofmaenner, D. A. et al. The many roles of cholesterol in sepsis: a review. Am. J. Respir. Crit. Care Med. 205, 388–396 (2022).
Lee, M. S. & Bensinger, S. J. Reprogramming cholesterol metabolism in macrophages and its role in host defense against cholesterol-dependent cytolysins. Cell Mol. Immunol. 19, 327–336 (2022).
Yan, J. & Horng, T. Lipid metabolism in regulation of macrophage functions. Trends Cell Biol. 30, 979–989 (2020).
Duewell, P. et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464, 1357–1361 (2010).
Jin, M. et al. Regulation of toll-like receptor (TLR) signaling pathways in atherosclerosis: from mechanisms to targeted therapeutics. Acta Pharm. Sin. 44, 2358–2375 (2023).
Soraci, L. et al. Toll-like receptors and NLRP3 inflammasome-dependent pathways in Parkinson’s disease: mechanisms and therapeutic implications. J. Neurol. 270, 1346–1360 (2023).
Rouvray, S. & Drummond, R. A. The role of lipids in regulating macrophage antifungal immunity. mBio 15, e0305723 (2024).
Niyonzima, N. et al. Mitochondrial C5aR1 activity in macrophages controls IL-1beta production underlying sterile inflammation. Sci. Immunol. 6, eabf2489 (2021).
Wang, C. et al. Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and decreases synaptic phagocytosis by microglia. Neuron 109, 1657–1674.e1657 (2021).
Wang, H. et al. Regulation of beta-amyloid production in neurons by astrocyte-derived cholesterol. Proc. Natl. Acad. Sci. USA 118, e2102191118 (2021).
Proto, J. D. et al. Hypercholesterolemia induces T cell expansion in humanized immune mice. J. Clin. Investig. 128, 2370–2375 (2018).
Li, J., Lu, E., Yi, T. & Cyster, J. G. EBI2 augments Tfh cell fate by promoting interaction with IL-2-quenching dendritic cells. Nature 533, 110–114 (2016).
Li, G., Park, H. J., Suh, J. H. & Choi, H. S. 7-Ketocholesterol plays a key role in cholesterol-induced hepatitis via macrophage and neutrophil infiltration. J. Nutr. Biochem. 125, 109552 (2024).
Westerterp, M. et al. Cholesterol efflux pathways suppress inflammasome activation, NETosis, and atherogenesis. Circulation 138, 898–912 (2018).
Thomas, D. G. et al. LXR suppresses inflammatory gene expression and neutrophil migration through cis-repression and cholesterol efflux. Cell Rep. 25, 3774–3785.e3774 (2018).
Morino, K. et al. Cholesterol sulfate limits neutrophil recruitment and gut inflammation during mucosal injury. Front. Immunol. 14, 1131146 (2023).
You, Z. & Chi, H. Lipid metabolism in dendritic cell biology. Immunol. Rev. 317, 137–151 (2023).
Yeh, Y. F. & Huang, S. L. Enhancing effect of dietary cholesterol and inhibitory effect of pravastatin on allergic pulmonary inflammation. J. Biomed. Sci. 11, 599–606 (2004).
Thompson, B. et al. Secondary bile acids function through the vitamin D receptor in myeloid progenitors to promote myelopoiesis. Blood Adv. 7, 4970–4982 (2023).
Wang, L. et al. Gut microbial bile acid metabolite skews macrophage polarization and contributes to high-fat diet-induced colonic inflammation. Gut Microbes 12, 1–20 (2020).
Huang, C. et al. Maternal Western diet mediates susceptibility of offspring to Crohn’s-like colitis by deoxycholate generation. Microbiome 11, 96 (2023).
Sun, H. et al. Gut commensal Parabacteroides distasonis alleviates inflammatory arthritis. Gut 72, 1664–1677 (2023).
Hang, S. et al. Bile acid metabolites control T(H)17 and T(reg) cell differentiation. Nature 576, 143–148 (2019).
Li, W. et al. A bacterial bile acid metabolite modulates T(reg) activity through the nuclear hormone receptor NR4A1. Cell Host Microbe 29, 1366–1377.e1369 (2021).
Campbell, C. et al. Bacterial metabolism of bile acids promotes generation of peripheral regulatory T cells. Nature 581, 475–479 (2020).
Devlin, A. S. & Fischbach, M. A. A biosynthetic pathway for a prominent class of microbiota-derived bile acids. Nat. Chem. Biol. 11, 685–690 (2015).
Sato, Y. et al. Novel bile acid biosynthetic pathways are enriched in the microbiome of centenarians. Nature 599, 458–464 (2021).
Arpaia, N. et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 504, 451–455 (2013).
Song, X. et al. Microbial bile acid metabolites modulate gut RORgamma(+) regulatory T cell homeostasis. Nature 577, 410–415 (2020).
Tatsugami, M. et al. Bile acid promotes intestinal metaplasia and gastric carcinogenesis. Cancer Epidemiol. Biomark. Prev. 21, 2101–2107 (2012).
Balazs, I. et al. Serum bile acids in liver cirrhosis promote neutrophil dysfunction. Clin. Transl. Med. 12, e735 (2022).
Quist, R. G. et al. Activation of mast cells by bile acids. Gastroenterology 101, 446–456 (1991).
Kim, E. J. et al. Ursodeoxycholic acid alleviates atopic dermatitis-associated inflammatory responses in HaCaT and RBL-2H3 cells and DNCB/DFE-treated mice. Life Sci. 344, 122560 (2024).
Meng, F. et al. Ursodeoxycholate inhibits mast cell activation and reverses biliary injury and fibrosis in Mdr2(-/-) mice and human primary sclerosing cholangitis. Lab. Investig. 98, 1465–1477 (2018).
Yamazaki, K., Gleich, G. J. & Kita, H. Bile acids induce eosinophil degranulation by two different mechanisms. Hepatology 33, 582–590 (2001).
Macian, F. NFAT proteins: key regulators of T-cell development and function. Nat. Rev. Immunol. 5, 472–484 (2005).
Lee, J. U., Kim, L. K. & Choi, J. M. Revisiting the concept of targeting NFAT to control T cell immunity and autoimmune diseases. Front. Immunol. 9, 2747 (2018).
Kiani, A. et al. Regulation of interferon-gamma gene expression by nuclear factor of activated T cells. Blood 98, 1480–1488 (2001).
Tang, D. et al. All-trans-retinoic acid shifts Th1 towards Th2 cell differentiation by targeting NFAT1 signalling to ameliorate immune-mediated aplastic anaemia. Br. J. Haematol. 191, 906–919 (2020).
Ranger, A. M., Oukka, M., Rengarajan, J. & Glimcher, L. H. Inhibitory function of two NFAT family members in lymphoid homeostasis and Th2 development. Immunity 9, 627–635 (1998).
Yoshida, H. et al. The transcription factor NF-ATc1 regulates lymphocyte proliferation and Th2 cytokine production. Immunity 8, 115–124 (1998).
Ranger, A. M. et al. Delayed lymphoid repopulation with defects in IL-4-driven responses produced by inactivation of NF-ATc. Immunity 8, 125–134 (1998).
Vymazal, O. et al. Immunosuppression affects neutrophil functions: does calcineurin-NFAT signaling matter?. Front. Immunol. 12, 770515 (2021).
Vymazal, O. et al. Calcineurin-NFAT signaling controls neutrophils’ ability of chemoattraction upon fungal infection. J. Leukoc. Biol. 116, 816–829 (2024).
Olenchock, B. A. et al. Disruption of diacylglycerol metabolism impairs the induction of T cell anergy. Nat. Immunol. 7, 1174–1181 (2006).
Shin, J., O’Brien, T. F., Grayson, J. M. & Zhong, X. P. Differential regulation of primary and memory CD8 T cell immune responses by diacylglycerol kinases. J. Immunol. 188, 2111–2117 (2012).
Oh, B. C. Phosphoinositides and intracellular calcium signaling: novel insights into phosphoinositides and calcium coupling as negative regulators of cellular signaling. Exp. Mol. Med. 55, 1702–1712 (2023).
Fruman, D. A. & Bismuth, G. Fine-tuning the immune response with PI3K. Immunol. Rev. 228, 253–272 (2009).
Nakanishi, A., Wada, Y., Kitagishi, Y. & Matsuda, S. Link between PI3K/AKT/PTEN pathway and NOX protein in diseases. Aging Dis. 5, 203–211 (2014).
Mishra, S. et al. Sirtuin 6 inhibition protects against glucocorticoid-induced skeletal muscle atrophy by regulating IGF/PI3K/AKT signaling. Nat. Commun. 13, 5415 (2022).
Yusuf, I. et al. Optimal B-cell proliferation requires phosphoinositide 3-kinase-dependent inactivation of FOXO transcription factors. Blood 104, 784–787 (2004).
Lees, J., Hay, J., Moles, M. W. & Michie, A. M. The discrete roles of individual FOXO transcription factor family members in B-cell malignancies. Front. Immunol. 14, 1179101 (2023).
Szydlowski, M., Jablonska, E. & Juszczynski, P. FOXO1 transcription factor: a critical effector of the PI3K-AKT axis in B-cell development. Int. Rev. Immunol. 33, 146–157 (2014).
Calamito, M. et al. Akt1 and Akt2 promote peripheral B-cell maturation and survival. Blood 115, 4043–4050 (2010).
Suzuki, H. et al. Xid-like immunodeficiency in mice with disruption of the p85alpha subunit of phosphoinositide 3-kinase. Science 283, 390–392 (1999).
Fruman, D. A. et al. Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85alpha. Science 283, 393–397 (1999).
Lin, L., Hron, J. D. & Peng, S. L. Regulation of NF-kappaB, Th activation, and autoinflammation by the forkhead transcription factor Foxo3a. Immunity 21, 203–213 (2004).
Xiang, M. et al. Kinsenoside attenuates liver fibro-inflammation by suppressing dendritic cells via the PI3K-AKT-FoxO1 pathway. Pharm. Res. 177, 106092 (2022).
Pan, T. et al. Immune effects of PI3K/Akt/HIF-1alpha-regulated glycolysis in polymorphonuclear neutrophils during sepsis. Crit. Care 26, 29 (2022).
Jiang, Y. et al. Knockdown of CCR3 gene inhibits proliferation, migration and degranulation of eosinophils in mice by downregulating the PI3K/Akt pathway. Int. Immunopharmacol. 113, 109439 (2022).
Wang, Y. et al. Silibinin attenuated pseudo-allergic reactions and mast cell degranulation via PLCgamma and PI3K/Akt signaling pathway. Phytother. Res. 37, 3572–3582 (2023).
Zhang, F. et al. MrgprX2 regulates mast cell degranulation through PI3K/AKT and PLCgamma signaling in pseudo-allergic reactions. Int. Immunopharmacol. 102, 108389 (2022).
Maceyka, M. & Spiegel, S. Sphingolipid metabolites in inflammatory disease. Nature 510, 58–67 (2014).
Lyapina, E. et al. Structural basis for receptor selectivity and inverse agonism in S1P(5) receptors. Nat. Commun. 13, 4736 (2022).
Wang, J. et al. Review article: the sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis—a unique therapeutic target in inflammatory bowel disease. Aliment. Pharm. Ther. 55, 277–291 (2022).
Cyster, J. G. & Schwab, S. R. Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs. Annu. Rev. Immunol. 30, 69–94 (2012).
Spiegel, S. & Milstien, S. The outs and the ins of sphingosine-1-phosphate in immunity. Nat. Rev. Immunol. 11, 403–415 (2011).
Hughes, J. E. et al. Sphingosine-1-phosphate induces an antiinflammatory phenotype in macrophages. Circ. Res. 102, 950–958 (2008).
Nofer, J. R. et al. FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 115, 501–508 (2007).
Duenas, A. I. et al. Selective attenuation of Toll-like receptor 2 signalling may explain the atheroprotective effect of sphingosine 1-phosphate. Cardiovasc. Res. 79, 537–544 (2008).
Weigert, A. et al. Apoptotic cells promote macrophage survival by releasing the antiapoptotic mediator sphingosine-1-phosphate. Blood 108, 1635–1642 (2006).
Tian, L. et al. S1P/S1PR1 signaling differentially regulates the allogeneic response of CD4 and CD8 T cells by modulating mitochondrial fission. Cell Mol. Immunol. 19, 1235–1250 (2022).
Krebs, C. F. et al. Autoimmune renal disease is exacerbated by s1p-receptor-1-dependent intestinal Th17 cell migration to the kidney. Immunity 45, 1078–1092 (2016).
Liu, G. et al. The S1P(1)-mTOR axis directs the reciprocal differentiation of T(H)1 and T(reg) cells. Nat. Immunol. 11, 1047–1056 (2010).
Rosen, H. & Goetzl, E. J. Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network. Nat. Rev. Immunol. 5, 560–570 (2005).
Jin, Y. et al. Sphingosine 1-phosphate is a novel inhibitor of T-cell proliferation. Blood 101, 4909–4915 (2003).
Zhao, X. et al. Neutrophil recruitment mediated by sphingosine 1-phosphate (S1P)/S1P receptors during chronic liver injury. Cell Immunol. 359, 104243 (2021).
Jones, B. A. et al. Farnesoid X receptor prevents neutrophil extracellular traps via reduced sphingosine-1-phosphate in chronic kidney disease. Am. J. Physiol. Ren. Physiol. 325, F792–F810 (2023).
Saluja, R. et al. Role of sphingosine-1-phosphate in mast cell functions and asthma and its regulation by non-coding RNA. Front. Immunol. 8, 587 (2017).
Olivera, A. et al. The sphingosine kinase-sphingosine-1-phosphate axis is a determinant of mast cell function and anaphylaxis. Immunity 26, 287–297 (2007).
Greenlee, J. D., Subramanian, T., Liu, K. & King, M. R. Rafting down the metastatic cascade: the role of lipid rafts in cancer metastasis, cell death, and clinical outcomes. Cancer Res. 81, 5–17 (2021).
Varshney, P., Yadav, V. & Saini, N. Lipid rafts in immune signalling: current progress and future perspective. Immunology 149, 13–24 (2016).
Sproul, T. W., Malapati, S., Kim, J. & Pierce, S. K. Cutting edge: B cell antigen receptor signaling occurs outside lipid rafts in immature B cells. J. Immunol. 165, 6020–6023 (2000).
Brodie, E. J., Infantino, S., Low, M. S. Y. & Tarlinton, D. M. Lyn, Lupus, and (B) lymphocytes, a lesson on the critical balance of kinase signaling in immunity. Front. Immunol. 9, 401 (2018).
Corneth, O. B. J., Neys, S. F. H. & Hendriks, R. W. Aberrant B cell signaling in autoimmune diseases. Cells 11, 3391 (2022).
Chen, L. et al. SYK inhibition modulates distinct PI3K/AKT-dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas. Cancer Cell 23, 826–838 (2013).
Saeki, K. et al. The B cell-specific major raft protein, Raftlin, is necessary for the integrity of lipid raft and BCR signal transduction. EMBO J. 22, 3015–3026 (2003).
Horejsi, V. The roles of membrane microdomains (rafts) in T cell activation. Immunol. Rev. 191, 148–164 (2003).
Dinur-Schejter, Y., Zaidman, I., Mor-Shaked, H. & Stepensky, P. The clinical aspect of adaptor molecules in T cell signaling: lessons learnt from inborn errors of immunity. Front. Immunol. 12, 701704 (2021).
Malissen, B. & Bongrand, P. Early T cell activation: integrating biochemical, structural, and biophysical cues. Annu. Rev. Immunol. 33, 539–561 (2015).
Smith-Garvin, J. E., Koretzky, G. A. & Jordan, M. S. T cell activation. Annu. Rev. Immunol. 27, 591–619 (2009).
Yablonski, D. Bridging the gap: modulatory roles of the Grb2-family adaptor, gads, in cellular and allergic immune responses. Front. Immunol. 10, 1704 (2019).
Devkota, S. et al. Scaffold protein SLP-76 primes PLCgamma1 for activation by ITK-mediated phosphorylation. J. Mol. Biol. 427, 2734–2747 (2015).
Puranik, N., Jung, H. & Song, M. SPROUTY2, a negative feedback regulator of receptor tyrosine kinase signaling, associated with neurodevelopmental disorders: current knowledge and future perspectives. Int. J. Mol. Sci. 25, 11043 (2024).
Zhu, Y. et al. Lowering glycosphingolipid levels in CD4+ T cells attenuates T cell receptor signaling, cytokine production, and differentiation to the Th17 lineage. J. Biol. Chem. 286, 14787–14794 (2011).
Nagafuku, M. et al. CD4 and CD8 T cells require different membrane gangliosides for activation. Proc. Natl. Acad. Sci. USA 109, E336–E342 (2012).
Fan, Q. et al. Hyper alpha2,6-sialylation promotes CD4(+) T-cell activation and induces the occurrence of ulcerative colitis. Adv. Sci. 10, e2302607 (2023).
Shouman, S. et al. SARS-CoV-2-associated lymphopenia: possible mechanisms and the role of CD147. Cell Commun. Signal 22, 349 (2024).
Pearce, E. L., Poffenberger, M. C., Chang, C. H. & Jones, R. G. Fueling immunity: insights into metabolism and lymphocyte function. Science 342, 1242454 (2013).
de Macedo, C. S. et al. New insights into the pathogenesis of leprosy: contribution of subversion of host cell metabolism to bacterial persistence, disease progression, and transmission. F1000Research 9 (2020).
Zhou, X. et al. Stearoyl-CoA desaturase-mediated monounsaturated fatty acid availability supports humoral immunity. Cell Rep. 34, 108601 (2021).
Dufort, F. J. et al. Glucose-dependent de novo lipogenesis in B lymphocytes: a requirement for ATP-citrate lyase in lipopolysaccharide-induced differentiation. J. Biol. Chem. 289, 7011–7024 (2014).
Shimabukuro-Vornhagen, A. et al. Inhibition of protein geranylgeranylation specifically interferes with CD40-dependent B cell activation, resulting in a reduced capacity to induce T cell immunity. J. Immunol. 193, 5294–5305 (2014).
Trub, A. G. et al. Statin therapy inhibits fatty acid synthase via dynamic protein modifications. Nat. Commun. 13, 2542 (2022).
Tajbakhsh, A. et al. Statin-regulated phagocytosis and efferocytosis in physiological and pathological conditions. Pharm. Ther. 238, 108282 (2022).
Bibby, J. A. et al. Cholesterol metabolism drives regulatory B cell IL-10 through provision of geranylgeranyl pyrophosphate. Nat. Commun. 11, 3412 (2020).
Kaymak, I. et al. ACLY and ACSS2 link nutrient-dependent chromatin accessibility to CD8 T cell effector responses. J. Exp. Med. 221, e20231820 (2024).
Tang, Y., Chen, Z., Zuo, Q. & Kang, Y. Regulation of CD8+ T cells by lipid metabolism in cancer progression. Cell Mol. Immunol. 21, 1215–1230 (2024).
Chowdhury, S. et al. Intracellular acetyl CoA potentiates the therapeutic efficacy of antitumor CD8+ T cells. Cancer Res. 82, 2640–2655 (2022).
Schulz-Kuhnt, A. et al. ATP citrate lyase (ACLY)-dependent immunometabolism in mucosal T cells drives experimental colitis in vivo. Gut 73, 601–612 (2024).
Hunt, E. G. et al. Acetyl-CoA carboxylase obstructs CD8(+) T cell lipid utilization in the tumor microenvironment. Cell Metab. 36, 969–983.e910 (2024).
Huang, J. et al. FASN inhibition decreases MHC-I degradation and synergizes with PD-L1 checkpoint blockade in hepatocellular carcinoma. Cancer Res 84, 855–871 (2024).
O’Sullivan, D. et al. Memory CD8(+) T cells use cell-intrinsic lipolysis to support the metabolic programming necessary for development. Immunity 41, 75–88 (2014).
Lim, S. A. et al. Lipid signalling enforces functional specialization of T(reg) cells in tumours. Nature 591, 306–311 (2021).
Timilshina, M. et al. Activation of mevalonate pathway via LKB1 is essential for stability of T(reg) cells. Cell Rep. 27, 2948–2961 e2947 (2019).
Zeng, H. et al. mTORC1 couples immune signals and metabolic programming to establish T(reg)-cell function. Nature 499, 485–490 (2013).
Xia, Y. et al. The mevalonate pathway is a druggable target for vaccine adjuvant discovery. Cell 175, 1059–1073.e1021 (2018).
Lodhi, I. J. et al. Peroxisomal lipid synthesis regulates inflammation by sustaining neutrophil membrane phospholipid composition and viability. Cell Metab. 21, 51–64 (2015).
Riffelmacher, T. et al. Autophagy-dependent generation of free fatty acids is critical for normal neutrophil differentiation. Immunity 47, 466–480.e465 (2017).
Everts, B. et al. TLR-driven early glycolytic reprogramming via the kinases TBK1-IKKvarepsilon supports the anabolic demands of dendritic cell activation. Nat. Immunol. 15, 323–332 (2014).
Nomura, M. et al. Macrophage fatty acid oxidation inhibits atherosclerosis progression. J. Mol. Cell Cardiol. 127, 270–276 (2019).
Genoula, M. et al. Fatty acid oxidation of alternatively activated macrophages prevents foam cell formation, but Mycobacterium tuberculosis counteracts this process via HIF-1alpha activation. PLoS Pathog. 16, e1008929 (2020).
Karmaus, P. W. F. et al. Metabolic heterogeneity underlies reciprocal fates of T(H)17 cell stemness and plasticity. Nature 565, 101–105 (2019).
Pearce, E. L. et al. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature 460, 103–107 (2009).
van der Windt, G. J. et al. Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development. Immunity 36, 68–78 (2012).
Cui, G. et al. IL-7-induced glycerol transport and TAG synthesis promotes memory CD8+ T Cell longevity. Cell 161, 750–761 (2015).
Raud, B. et al. Etomoxir actions on regulatory and memory T cells are independent of Cpt1a-mediated fatty acid oxidation. Cell Metab. 28, 504–515.e507 (2018).
Zhang, C. et al. STAT3 activation-induced fatty acid oxidation in CD8(+) T effector cells is critical for obesity-promoted breast tumor growth. Cell Metab. 31, 148–161 e145 (2020).
Ringel, A. E. et al. Obesity shapes metabolism in the tumor microenvironment to suppress anti-tumor immunity. Cell 183, 1848–1866.e1826 (2020).
Pan, Y. et al. Survival of tissue-resident memory T cells requires exogenous lipid uptake and metabolism. Nature 543, 252–256 (2017).
Frizzell, H. et al. Organ-specific isoform selection of fatty acid-binding proteins in tissue-resident lymphocytes. Sci. Immunol. 5, eaay9283 (2020).
Lin, R. et al. Fatty acid oxidation controls CD8(+) tissue-resident memory T-cell survival in gastric adenocarcinoma. Cancer Immunol. Res. 8, 479–492 (2020).
Field, C. S. et al. Mitochondrial integrity regulated by lipid metabolism is a cell-intrinsic checkpoint for Treg suppressive function. Cell Metab. 31, 422–437.e425 (2020).
Hochrein, S. M. et al. The glucose transporter GLUT3 controls T helper 17 cell responses through glycolytic-epigenetic reprogramming. Cell Metab. 34, 516–532.e511 (2022).
Jaccard, A. et al. Reductive carboxylation epigenetically instructs T cell differentiation. Nature 621, 849–856 (2023).
Pae, J. & Victora, G. D. B is for ‘Big Mac’: GCs crave a high-fat diet. Nat. Immunol. 21, 249–250 (2020).
Sankar, P. et al. Fatty acid metabolism in neutrophils promotes lung damage and bacterial replication during tuberculosis. PLoS Pathog. 20, e1012188 (2024).
Pham, L. et al. Neutrophil trafficking to the site of infection requires Cpt1a-dependent fatty acid beta-oxidation. Commun. Biol. 5, 1366 (2022).
Toller-Kawahisa, J. E. & O’Neill, L. A. J. How neutrophil metabolism affects bacterial killing. Open Biol. 12, 220248 (2022).
Hoy, A. J., Nagarajan, S. R. & Butler, L. M. Tumour fatty acid metabolism in the context of therapy resistance and obesity. Nat. Rev. Cancer 21, 753–766 (2021).
Chen, I. C. et al. High-fat diet-induced obesity alters dendritic cell homeostasis by enhancing mitochondrial fatty acid oxidation. J. Immunol. 209, 69–76 (2022).
Li, Y. et al. Microglial lipid droplet accumulation in tauopathy brain is regulated by neuronal AMPK. Cell Metab. 36, 1351–1370.e1358 (2024).
Maestri, A. et al. Lipid droplets, autophagy, and ageing: a cell-specific tale. Ageing Res. Rev. 94, 102194 (2024).
Howie, D. et al. A novel role for triglyceride metabolism in Foxp3 expression. Front Immunol. 10, 1860 (2019).
Trempolec, N. et al. Acidosis-induced TGF-beta2 production promotes lipid droplet formation in dendritic cells and alters their potential to support anti-mesothelioma T cell response. Cancers12, 1284 (2020).
Gao, A. et al. Tumor-derived ILT4 induces T cell senescence and suppresses tumor immunity. J. Immunother. Cancer 9, e001536 (2021).
Huang, Y. L. et al. Toll-like receptor agonists promote prolonged triglyceride storage in macrophages. J. Biol. Chem. 289, 3001–3012 (2014).
D’Avila, H. et al. Host cell lipid bodies triggered by Trypanosoma cruzi infection and enhanced by the uptake of apoptotic cells are associated with prostaglandin E(2) generation and increased parasite growth. J. Infect. Dis. 204, 951–961 (2011).
Almeida, P. E. et al. Differential TLR2 downstream signaling regulates lipid metabolism and cytokine production triggered by Mycobacterium bovis BCG infection. Biochim. Biophys. Acta 1841, 97–107 (2014).
Lammers, B. et al. Macrophage adipose triglyceride lipase deficiency attenuates atherosclerotic lesion development in low-density lipoprotein receptor knockout mice. Arterioscler. Thromb. Vasc. Biol. 31, 67–73 (2011).
van Dierendonck, X. et al. Triglyceride breakdown from lipid droplets regulates the inflammatory response in macrophages. Proc. Natl. Acad. Sci. USA 119, e2114739119 (2022).
Chandak, P. G. et al. Efficient phagocytosis requires triacylglycerol hydrolysis by adipose triglyceride lipase. J. Biol. Chem. 285, 20192–20201 (2010).
Bougneres, L. et al. A role for lipid bodies in the cross-presentation of phagocytosed antigens by MHC class I in dendritic cells. Immunity 31, 232–244 (2009).
Veglia, F. et al. Lipid bodies containing oxidatively truncated lipids block antigen cross-presentation by dendritic cells in cancer. Nat. Commun. 8, 2122 (2017).
Ji, X., Wu, L., Marion, T. & Luo, Y. Lipid metabolism in regulation of B cell development and autoimmunity. Cytokine Growth Factor Rev. 73, 40–51 (2023).
Hu, T. et al. Metabolic regulation of the immune system in health and diseases: mechanisms and interventions. Signal Transduct. Target Ther. 9, 268 (2024).
Liu, W. W. et al. RNA modifications in cellular metabolism: implications for metabolism-targeted therapy and immunotherapy. Signal Transduct. Target Ther. 9, 70 (2024).
Liu, S. et al. LncRNAs-circRNAs as rising epigenetic binary superstars in regulating lipid metabolic reprogramming of cancers. Adv. Sci.11, e2303570 (2024).
Xu, X. et al. Metabolic reprogramming and epigenetic modifications in cancer: from the impacts and mechanisms to the treatment potential. Exp. Mol. Med 55, 1357–1370 (2023).
Grabner, G. F., Xie, H., Schweiger, M. & Zechner, R. Lipolysis: cellular mechanisms for lipid mobilization from fat stores. Nat. Metab. 3, 1445–1465 (2021).
Yang, X. F. & Shang, D. J. The role of peroxisome proliferator-activated receptor gamma in lipid metabolism and inflammation in atherosclerosis. Cell Biol. Int. 47, 1469–1487 (2023).
Stark, J. M., Coquet, J. M. & Tibbitt, C. A. The role of PPAR-gamma in allergic disease. Curr. Allergy Asthma Rep. 21, 45 (2021).
Liu, Y. et al. The roles of PPARgamma and its agonists in autoimmune diseases: a comprehensive review. J. Autoimmun. 113, 102510 (2020).
Zuo, S. et al. Lipid synthesis, triggered by PPARgamma T166 dephosphorylation, sustains reparative function of macrophages during tissue repair. Nat. Commun. 15, 7269 (2024).
Liu, S. et al. S100A4 enhances protumor macrophage polarization by control of PPAR-gamma-dependent induction of fatty acid oxidation. J. Immunother. Cancer 9, e002548 (2021).
Masuyama, S. et al. Enhanced fatty acid oxidation by selective activation of PPARalpha alleviates autoimmunity through metabolic transformation in T-cells. Clin. Immunol. 268, 110357 (2024).
Guo, X. et al. PPAR-alpha agonist fenofibrate ameliorates sjogren syndrome-like dacryoadenitis by modulating Th1/Th17 and Treg cell responses in NOD mice. Investig. Ophthalmol. Vis. Sci. 63, 12 (2022).
Nencioni, A. et al. Dendritic cell immunogenicity is regulated by peroxisome proliferator-activated receptor gamma. J. Immunol. 169, 1228–1235 (2002).
Woerly, G. et al. Peroxisome proliferator-activated receptors alpha and gamma down-regulate allergic inflammation and eosinophil activation. J. Exp. Med. 198, 411–421 (2003).
Shen, S. et al. SIRT1/SREBPs-mediated regulation of lipid metabolism. Pharm. Res. 199, 107037 (2024).
Li, Y. et al. Key events in cancer: dysregulation of SREBPs. Front. Pharm. 14, 1130747 (2023).
Guan, D. et al. Hepatocyte SREBP signaling mediates clock communication within the liver. J. Clin. Investig. 133, e163018 (2023).
Lee, J. H. et al. SCAP deficiency facilitates obesity and insulin resistance through shifting adipose tissue macrophage polarization. J. Adv. Res. 45, 1–13 (2023).
Im, S. S. et al. Linking lipid metabolism to the innate immune response in macrophages through sterol regulatory element binding protein-1a. Cell Metab. 13, 540–549 (2011).
Oishi, Y. et al. SREBP1 contributes to resolution of pro-inflammatory TLR4 signaling by reprogramming fatty acid metabolism. Cell Metab. 25, 412–427 (2017).
Kidani, Y. et al. Sterol regulatory element-binding proteins are essential for the metabolic programming of effector T cells and adaptive immunity. Nat. Immunol. 14, 489–499 (2013).
Zhu, L. et al. Fatostatin promotes anti-tumor immunity by reducing SREBP2-mediated cholesterol metabolism in tumor-infiltrating T lymphocytes. Eur. J. Pharm. 971, 176519 (2024).
Yang, K. et al. T cell exit from quiescence and differentiation into Th2 cells depend on Raptor-mTORC1-mediated metabolic reprogramming. Immunity 39, 1043–1056 (2013).
Berod, L. et al. De novo fatty acid synthesis controls the fate between regulatory T and T helper 17 cells. Nat. Med. 20, 1327–1333 (2014).
Cluxton, D., Petrasca, A., Moran, B. & Fletcher, J. M. Differential regulation of human Treg and Th17 cells by fatty acid synthesis and glycolysis. Front Immunol. 10, 115 (2019).
Luo, W. et al. SREBP signaling is essential for effective B cell responses. Nat. Immunol. 24, 337–348 (2023).
Wang, X. et al. Epigenetic regulation of macrophage polarization and inflammation by DNA methylation in obesity. JCI Insight 1, e87748 (2016).
Porcuna, J., Minguez-Martinez, J. & Ricote, M. The PPARalpha and PPARgamma epigenetic landscape in cancer and immune and metabolic disorders. Int J. Mol. Sci. 22, 10573 (2021).
Xu, L. & Cai, M. Tacrolimus maintains the balance of neutrophil extracellular traps by inducing DNA methylation of neutrophils to reduce immune rejection. Life13, 2253 (2023).
Singh Rawat, B., Venkataraman, R., Budhwar, R. & Tailor, P. Methionine- and choline-deficient diet identifies an essential role for DNA methylation in plasmacytoid dendritic cell biology. J. Immunol. 208, 881–897 (2022).
Price, N. L. et al. Loss of hepatic miR-33 improves metabolic homeostasis and liver function without altering body weight or atherosclerosis. Proc. Natl. Acad. Sci. USA 118, e2006478118 (2021).
Chen, H. et al. LncRNA HOTAIR inhibits miR-19a-3p to alleviate foam cell formation and inflammatory response in atherosclerosis. Int. J. Med. Sci. 21, 521–529 (2024).
Tian, F. J. et al. Elevated microRNA-155 promotes foam cell formation by targeting HBP1 in atherogenesis. Cardiovasc Res. 103, 100–110 (2014).
Wang, G. et al. CTRP12 ameliorates atherosclerosis by promoting cholesterol efflux and inhibiting inflammatory response via the miR-155-5p/LXRalpha pathway. Cell Death Dis. 12, 254 (2021).
Garley, M., Nowak, K. & Jablonska, E. Neutrophil microRNAs. Biol. Rev. Camb. Philos. Soc. 99, 864–877 (2024).
Lin, Z. et al. microRNA-144/451 decreases dendritic cell bioactivity via targeting interferon-regulatory factor 5 to limit DSS-induced colitis. Front. Immunol. 13, 928593 (2022).
Meng, Y. et al. MicroRNA-148a facilitates inflammatory dendritic cell differentiation and autoimmunity by targeting MAFB. JCI Insight 5, e133721 (2020).
Cordeiro, B. et al. MicroRNA-9 fine-tunes dendritic cell function by suppressing negative regulators in a cell-type-specific manner. Cell Rep. 31, 107585 (2020).
Deng, Q. et al. Mast cell-mediated microRNA functioning in immune regulation and disease pathophysiology. Clin. Exp. Med. 25, 38 (2025).
Liu, S., Wu, J., Tong, X. & Huang, L. H. A novel target to turn cold tumors into hot tumors: lysosomal 25-hydroxycholesterol activates AMPKalpha and immunosuppressive tumor-associated macrophages. Cell Mol. Immunol. 21, 801–803 (2024).
Xiao, J. et al. 25-Hydroxycholesterol regulates lysosome AMP kinase activation and metabolic reprogramming to educate immunosuppressive macrophages. Immunity 57, 1087–1104.e1087 (2024).
Yang, Y. et al. Non-lethal sonodynamic therapy facilitates the M1-to-M2 transition in advanced atherosclerotic plaques via activating the ROS-AMPK-mTORC1-autophagy pathway. Redox Biol. 32, 101501 (2020).
Xu, W. et al. Autoantibody against beta(1)-adrenoceptor promotes the differentiation of natural regulatory T cells from activated CD4(+) T cells by up-regulating AMPK-mediated fatty acid oxidation. Cell Death Dis. 10, 158 (2019).
Chai, Q. et al. A bacterial phospholipid phosphatase inhibits host pyroptosis by hijacking ubiquitin. Science 378, eabq0132 (2022).
Ma, K. et al. Hepatocellular carcinoma LINC01116 outcompetes T cells for linoleic acid and accelerates tumor progression. Adv. Sci.11, e2400676 (2024).
Wu, J. et al. PPARgamma as an E3 ubiquitin-ligase impedes phosphate-Stat6 stability and promotes prostaglandins E(2)-mediated inhibition of IgE production in asthma. Front. Immunol. 11, 1224 (2020).
Ou, Q. et al. TcpC inhibits neutrophil extracellular trap formation by enhancing ubiquitination-mediated degradation of peptidylarginine deiminase 4. Nat. Commun. 12, 3481 (2021).
Tong, H. et al. Ubiquitin ligases CBL and CBL-B maintain the homeostasis and immune quiescence of dendritic cells. Front. Immunol. 12, 757231 (2021).
Ohmura-Hoshino, M. et al. Cutting edge: requirement of MARCH-I-mediated MHC II ubiquitination for the maintenance of conventional dendritic cells. J. Immunol. 183, 6893–6897 (2009).
Zhu, B. et al. Roles of ubiquitination and deubiquitination in regulating dendritic cell maturation and function. Front. Immunol. 11, 586613 (2020).
Gou, Y. et al. Ectopic endometriotic stromal cells-derived lactate induces M2 macrophage polarization via Mettl3/Trib1/ERK/STAT3 signalling pathway in endometriosis. Immunology 168, 389–402 (2023).
Calis, J. J. A. & van Loosdregt, J. N(6)-adenosine methylation (m(6)A) is involved in the life and death decisions of T cells. Cell Mol. Immunol. 20, 316–317 (2023).
Li, H. B. et al. m(6)A mRNA methylation controls T cell homeostasis by targeting the IL-7/STAT5/SOCS pathways. Nature 548, 338–342 (2017).
Ito-Kureha, T. et al. The function of Wtap in N(6)-adenosine methylation of mRNAs controls T cell receptor signaling and survival of T cells. Nat. Immunol. 23, 1208–1221 (2022).
Zheng, Z. et al. Control of early B cell development by the RNA N(6)-methyladenosine methylation. Cell Rep. 31, 107819 (2020).
Huang, H. et al. Mettl14-mediated m6A modification is essential for germinal center B cell response. J. Immunol. 208, 1924–1936 (2022).
Luo, S. et al. METTL3-mediated m6A mRNA methylation regulates neutrophil activation through targeting TLR4 signaling. Cell Rep. 42, 112259 (2023).
Liu, Y. et al. m(6)A demethylase ALKBH5 is required for antibacterial innate defense by intrinsic motivation of neutrophil migration. Signal Transduct. Target Ther. 7, 194 (2022).
Liu, Y. et al. The RNA m(6)A demethylase ALKBH5 drives emergency granulopoiesis and neutrophil mobilization by upregulating G-CSFR expression. Cell Mol. Immunol. 21, 6–18 (2024).
Conrad, N. et al. Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK. Lancet 401, 1878–1890 (2023).
Wojcik, P., Gegotek, A., Zarkovic, N. & Skrzydlewska, E. Oxidative stress and lipid mediators modulate immune cell functions in autoimmune diseases. Int J. Mol. Sci. 22, 723 (2021).
Yu, H., Bai, S., Hao, Y. & Guan, Y. Fatty acids role in multiple sclerosis as “metabokines”. J. Neuroinflamm. 19, 157 (2022).
Yuan, X. et al. Functional and metabolic alterations of gut microbiota in children with new-onset type 1 diabetes. Nat. Commun. 13, 6356 (2022).
Marino, E. et al. Gut microbial metabolites limit the frequency of autoimmune T cells and protect against type 1 diabetes. Nat. Immunol. 18, 552–562 (2017).
Zimmerman, M. A. et al. Butyrate suppresses colonic inflammation through HDAC1-dependent Fas upregulation and Fas-mediated apoptosis of T cells. Am. J. Physiol. Gastrointest. Liver Physiol. 302, G1405–G1415 (2012).
Parada Venegas, D. et al. Corrigendum: short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. Front. Immunol. 10, 1486 (2019).
Sanchez, H. N. et al. B cell-intrinsic epigenetic modulation of antibody responses by dietary fiber-derived short-chain fatty acids. Nat. Commun. 11, 60 (2020).
Maslowski, K. M. et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 461, 1282–1286 (2009).
Miller, S. J. et al. Short-chain fatty acids modulate gene expression for vascular endothelial cell adhesion molecules. Nutrition 21, 740–748 (2005).
Balic, A. et al. Omega-3 versus omega-6 polyunsaturated fatty acids in the prevention and treatment of inflammatory skin diseases. Int. J. Mol. Sci. 21, 741 (2020).
Morin, S., Belanger, S., Cortez Ghio, S. & Pouliot, R. Eicosapentaenoic acid reduces the proportion of IL-17A-producing T cells in a 3D psoriatic skin model. J. Lipid Res. 64, 100428 (2023).
Bi, X. et al. omega-3 polyunsaturated fatty acids ameliorate type 1 diabetes and autoimmunity. J. Clin. Investig. 127, 1757–1771 (2017).
El Mahdy, R. N. et al. Eicosapentaenoic acid mitigates ulcerative colitis-induced by acetic acid through modulation of NF-kappaB and TGF-beta/ EGFR signaling pathways. Life Sci. 327, 121820 (2023).
Wen, H., Leong, P. M., Wang, X. & Li, D. Isolation and characterization of n-3 polyunsaturated fatty acids in enteromorpha prolifera lipids and their preventive effects on ulcerative colitis in C57BL/6J mice. Foods 13, 46 (2023).
Zhang, Z. et al. Differential effects of EPA and DHA on DSS-induced colitis in mice and possible mechanisms involved. Food Funct. 12, 1803–1817 (2021).
Hsieh, W. C. et al. PTPN2 links colonic and joint inflammation in experimental autoimmune arthritis. JCI Insight 5, e141868 (2020).
Qin, C. & Hagg, S. Associations between genetic variation in the targets of low-density lipoprotein-lowering drugs and rheumatoid arthritis. Circ. Genom. Precis Med 17, e004232 (2024).
Demkova, L. et al. Simultaneous deletion of ORMDL1 and ORMDL3 proteins disrupts immune cell homeostasis. Front. Immunol. 15, 1376629 (2024).
Broadfield, L. A. et al. Lipid metabolism in cancer: new perspectives and emerging mechanisms. Dev. Cell 56, 1363–1393 (2021).
Wei, W. et al. FBXW7beta loss-of-function enhances FASN-mediated lipogenesis and promotes colorectal cancer growth. Signal Transduct. Target Ther. 8, 187 (2023).
Jiang, L. et al. Up-regulated FASN expression promotes transcoelomic metastasis of ovarian cancer cells through epithelial-mesenchymal transition. Int. J. Mol. Sci. 15, 11539–11554 (2014).
Wang, H., Xi, Q. & Wu, G. Fatty acid synthase regulates invasion and metastasis of colorectal cancer via Wnt signaling pathway. Cancer Med. 5, 1599–1606 (2016).
Buckley, D. et al. Fatty acid synthase—modern tumor cell biology insights into a classical oncology target. Pharm. Ther. 177, 23–31 (2017).
Giese, M. A., Hind, L. E. & Huttenlocher, A. Neutrophil plasticity in the tumor microenvironment. Blood 133, 2159–2167 (2019).
Veglia, F. et al. Fatty acid transport protein 2 reprograms neutrophils in cancer. Nature 569, 73–78 (2019).
Shi, X. et al. Bladder-cancer-derived exosomal circRNA_0013936 promotes suppressive immunity by up-regulating fatty acid transporter protein 2 and down-regulating receptor-interacting protein kinase 3 in PMN-MDSCs. Mol. Cancer 23, 52 (2024).
Shi, X. et al. Feedback loop between fatty acid transport protein 2 and receptor-interacting protein 3 pathways promotes polymorphonuclear neutrophil myeloid-derived suppressor cells-potentiated suppressive immunity in bladder cancer. Mol. Biol. Rep. 49, 11643–11652 (2022).
Augimeri, G. et al. The role of PPARgamma ligands in breast cancer: from basic research to clinical studies. Cancers12, 2623 (2020).
Frankhouser, D. E. et al. Randomized dose-response trial of n-3 fatty acids in hormone receptor negative breast cancer survivors – impact on breast adipose oxylipin and DNA methylation patterns. Am. J. Clin. Nutr. 122, 70–82 (2025).
D’Eliseo, D. et al. Epitelial-to-mesenchimal transition and invasion are upmodulated by tumor-expressed granzyme B and inhibited by docosahexaenoic acid in human colorectal cancer cells. J. Exp. Clin. Cancer Res. 35, 24 (2016).
Janakiram, N. B., Mohammed, A. & Rao, C. V. Role of lipoxins, resolvins, and other bioactive lipids in colon and pancreatic cancer. Cancer Metastasis Rev. 30, 507–523 (2011).
Xiao, M. et al. Functional significance of cholesterol metabolism in cancer: from threat to treatment. Exp. Mol. Med. 55, 1982–1995 (2023).
Freed-Pastor, W. A. et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 148, 244–258 (2012).
Yue, S. et al. Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness. Cell Metab. 19, 393–406 (2014).
King, R. J., Singh, P. K. & Mehla, K. The cholesterol pathway: impact on immunity and cancer. Trends Immunol. 43, 78–92 (2022).
Liu, W. et al. Dysregulated cholesterol homeostasis results in resistance to ferroptosis increasing tumorigenicity and metastasis in cancer. Nat. Commun. 12, 5103 (2021).
Goossens, P. et al. Membrane cholesterol efflux drives tumor-associated macrophage reprogramming and tumor progression. Cell Metab. 29, 1376–1389 e1374 (2019).
Peng, S. et al. Metabolomics reveals that CAF-derived lipids promote colorectal cancer peritoneal metastasis by enhancing membrane fluidity. Int. J. Biol. Sci. 18, 1912–1932 (2022).
Nguyen, P. L. et al. Fatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survival. J. Clin. Oncol. 28, 3958–3964 (2010).
Wang, J. et al. Impact of genetic variants involved in the lipid metabolism pathway on progression-free survival in patients receiving bevacizumab-based chemotherapy in metastatic colorectal cancer: a retrospective analysis of FIRE-3 and MAVERICC trials. EClinicalMedicine 57, 101827 (2023).
He, Y., Chen, J., Ma, Y. & Chen, H. Apolipoproteins: new players in cancers. Front. Pharm. 13, 1051280 (2022).
Currie, E. et al. Cellular fatty acid metabolism and cancer. Cell Metab. 18, 153–161 (2013).
Collaborators, G. B. D. N. Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 18, 459–480 (2019).
Di Paolo, G. & Kim, T. W. Linking lipids to Alzheimer’s disease: cholesterol and beyond. Nat. Rev. Neurosci. 12, 284–296 (2011).
Guo, B. et al. Gut microbiota-derived short-chain fatty acids act as mediators of the gut-brain axis targeting age-related neurodegenerative disorders: a narrative review. Crit. Rev. Food Sci. Nutr. 65, 265–286 (2025).
Qing, H. et al. Valproic acid inhibits Abeta production, neuritic plaque formation, and behavioral deficits in Alzheimer’s disease mouse models. J. Exp. Med. 205, 2781–2789 (2008).
Haghikia, A. et al. Dietary fatty acids directly impact central nervous system autoimmunity via the small intestine. Immunity 44, 951–953 (2016).
Soliman, M. L., Puig, K. L., Combs, C. K. & Rosenberger, T. A. Acetate reduces microglia inflammatory signaling in vitro. J. Neurochem. 123, 555–567 (2012).
Matt, S. M. et al. Butyrate and dietary soluble fiber improve neuroinflammation associated with aging in mice. Front. Immunol. 9, 1832 (2018).
Morgese, M. G. et al. Depressive-like phenotype evoked by lifelong nutritional omega-3 deficiency in female rats: Crosstalk among kynurenine, toll-like receptors and amyloid beta oligomers. Brain Behav. Immun. 87, 444–454 (2020).
Ebright, B. et al. Effects of APOE4 on omega-3 brain metabolism across the lifespan. Trends Endocrinol. Metab. 35, 745–757 (2024).
Shirooie, S. et al. Targeting mTORs by omega-3 fatty acids: a possible novel therapeutic strategy for neurodegeneration?. Pharm. Res. 135, 37–48 (2018).
Yan, L. et al. Omega-3 polyunsaturated fatty acids promote brain-to-blood clearance of beta-Amyloid in a mouse model with Alzheimer’s disease. Brain Behav. Immun. 85, 35–45 (2020).
Ahmed, H. et al. Brain cholesterol and Alzheimer’s disease: challenges and opportunities in probe and drug development. Brain 147, 1622–1635 (2024).
Gao, Y. et al. Brain cholesterol homeostasis and its association with neurodegenerative diseases. Neurochem. Int. 171, 105635 (2023).
Li, D., Zhang, J. & Liu, Q. Brain cell type-specific cholesterol metabolism and implications for learning and memory. Trends Neurosci. 45, 401–414 (2022).
Yang, L. G., March, Z. M., Stephenson, R. A. & Narayan, P. S. Apolipoprotein E in lipid metabolism and neurodegenerative disease. Trends Endocrinol. Metab. 34, 430–445 (2023).
Pfrieger, F. W. & Ungerer, N. Cholesterol metabolism in neurons and astrocytes. Prog. Lipid Res. 50, 357–371 (2011).
Koch, M. et al. Association of apolipoprotein E in lipoprotein subspecies with risk of dementia. JAMA Netw. Open 3, e209250 (2020).
Robert, J. et al. Cerebrovascular amyloid angiopathy in bioengineered vessels is reduced by high-density lipoprotein particles enriched in Apolipoprotein E. Mol. Neurodegener. 15, 23 (2020).
Engel, S. et al. Is APOE epsilon4 associated with cognitive performance in early MS?. Neurol. Neuroimmunol. Neuroinflamm 7, e728 (2020).
Shao, Y. et al. The inhibition of ORMDL3 prevents Alzheimer’s disease through ferroptosis by PERK/ATF4/HSPA5 pathway. IET Nanobiotechnol. 17, 182–196 (2023).
Poliakova, T. & Wellington, C. L. Roles of peripheral lipoproteins and cholesteryl ester transfer protein in the vascular contributions to cognitive impairment and dementia. Mol. Neurodegener. 18, 86 (2023).
Sanders, A. E. et al. Association of a functional polymorphism in the cholesteryl ester transfer protein (CETP) gene with memory decline and incidence of dementia. JAMA 303, 150–158 (2010).
Vasan, R. S. & Benjamin, E. J. The future of cardiovascular epidemiology. Circulation 133, 2626–2633 (2016).
Collaborators, G. B. D. C. o. D. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392, 1736–1788 (2018).
Soppert, J. et al. Lipoproteins and lipids in cardiovascular disease: from mechanistic insights to therapeutic targeting. Adv. Drug Deliv. Rev. 159, 4–33 (2020).
Weber, C. & Noels, H. Atherosclerosis: current pathogenesis and therapeutic options. Nat. Med. 17, 1410–1422 (2011).
Li, M. et al. Time and concentration dependent effects of short chain fatty acids on lipopolysaccharide- or tumor necrosis factor alpha-induced endothelial activation. Front Pharm. 9, 233 (2018).
Mozaffarian, D. & Wu, J. H. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J. Am. Coll. Cardiol. 58, 2047–2067 (2011).
Bercea, C. I., Cottrell, G. S., Tamagnini, F. & McNeish, A. J. Omega-3 polyunsaturated fatty acids and hypertension: a review of vasodilatory mechanisms of docosahexaenoic acid and eicosapentaenoic acid. Br. J. Pharm. 178, 860–877 (2021).
Shirani, M. et al. Effects of marine-derived n-3 PUFA supplementation on soluble adhesion molecules: a systematic review and dose-response meta-analysis of randomized controlled trials. Pharm. Res 197, 106963 (2023).
Nordestgaard, B. G. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology. Circ. Res 118, 547–563 (2016).
Ross, R. & Harker, L. Hyperlipidemia and atherosclerosis. Science 193, 1094–1100 (1976).
Xing, Y. & Lin, X. Challenges and advances in the management of inflammation in atherosclerosis. J. Adv. Res. 71, 317–335 (2025).
Obermayer, G., Afonyushkin, T. & Binder, C. J. Oxidized low-density lipoprotein in inflammation-driven thrombosis. J. Thromb. Haemost. 16, 418–428 (2018).
Ishibashi, S. et al. Massive xanthomatosis and atherosclerosis in cholesterol-fed low-density lipoprotein receptor-negative mice. J. Clin. Investig. 93, 1885–1893 (1994).
Li, X. et al. Autophagy enhanced by curcumin ameliorates inflammation in atherogenesis via the TFEB-P300-BRD4 axis. Acta Pharm. Sin. B 12, 2280–2299 (2022).
Cimmino, G. et al. Oxidized low-density lipoproteins induce tissue factor expression in T-lymphocytes via activation of lectin-like oxidized low-density lipoprotein receptor-1. Cardiovasc Res. 116, 1125–1135 (2020).
Tsilingiri, K. et al. Oxidized low-density lipoprotein receptor in lymphocytes prevents atherosclerosis and predicts subclinical disease. Circulation 139, 243–255 (2019).
Wolf, D. & Ley, K. Immunity and inflammation in atherosclerosis. Circ. Res. 124, 315–327 (2019).
Tabas, I. & Bornfeldt, K. E. Macrophage phenotype and function in different stages of atherosclerosis. Circ. Res 118, 653–667 (2016).
Swiatlowska, P. et al. Hypertensive pressure mechanosensing alone triggers lipid droplet accumulation and transdifferentiation of vascular smooth muscle cells to foam cells. Adv. Sci.11, e2308686 (2024).
Linton, M. F., Yancey, P. G., Tao, H. & Davies, S. S. HDL function and atherosclerosis: reactive dicarbonyls as promising targets of therapy. Circ. Res. 132, 1521–1545 (2023).
Robichaud, S. et al. Identification of novel lipid droplet factors that regulate lipophagy and cholesterol efflux in macrophage foam cells. Autophagy 17, 3671–3689 (2021).
Mineo, C. & Shaul, P. W. Novel biological functions of high-density lipoprotein cholesterol. Circ. Res. 111, 1079–1090 (2012).
Yuhanna, I. S. et al. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat. Med. 7, 853–857 (2001).
Khalil, Y. A., Rabes, J. P., Boileau, C. & Varret, M. APOE gene variants in primary dyslipidemia. Atherosclerosis 328, 11–22 (2021).
Yu, C. et al. Genome-wide association study of cardiovascular resilience identifies protective variation in the CETP gene. J. Am. Heart Assoc. 12, e031459 (2023).
Li, X. et al. Inflammation and aging: signaling pathways and intervention therapies. Signal Transduct. Target Ther. 8, 239 (2023).
Munro, D. & Blier, P. U. The extreme longevity of Arctica islandica is associated with increased peroxidation resistance in mitochondrial membranes. Aging Cell 11, 845–855 (2012).
Gonzalez-Covarrubias, V. et al. Lipidomics of familial longevity. Aging Cell 12, 426–434 (2013).
Streeper, R. S. et al. Deficiency of the lipid synthesis enzyme, DGAT1, extends longevity in mice. Aging4, 13–27 (2012).
Schmeisser, S. et al. Muscle-specific lipid hydrolysis prolongs lifespan through global lipidomic remodeling. Cell Rep. 29, 4540–4552.e4548 (2019).
Zaarur, N. et al. ATGL-1 mediates the effect of dietary restriction and the insulin/IGF-1 signaling pathway on longevity in C. elegans. Mol. Metab. 27, 75–82 (2019).
Schachter, F. et al. Genetic associations with human longevity at the APOE and ACE loci. Nat. Genet. 6, 29–32 (1994).
Chen, H. et al. Causal effects of lipid-lowering therapies on aging-related outcomes and risk of cancers: a drug-target Mendelian randomization study. Aging15, 15228–15242 (2023).
Luo, A. et al. Epigenetic aging is accelerated in alcohol use disorder and regulated by genetic variation in APOL2. Neuropsychopharmacology 45, 327–336 (2020).
Mooijaart, S. P. et al. Liver X receptor alpha associates with human life span. J. Gerontol. A Biol. Sci. Med. Sci. 62, 343–349 (2007).
Mutlu, A. S., Duffy, J. & Wang, M. C. Lipid metabolism and lipid signals in aging and longevity. Dev. Cell 56, 1394–1407 (2021).
Israelsen, M., Francque, S., Tsochatzis, E. A. & Krag, A. Steatotic liver disease. Lancet 404, 1761–1778 (2024).
Younossi, Z. et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 15, 11–20 (2018).
Benede-Ubieto, R., Cubero, F. J. & Nevzorova, Y. A. Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD). Gut Microbes 16, 2331460 (2024).
Wang, S. et al. Metabolic disorders, inter-organ crosstalk, and inflammation in the progression of metabolic dysfunction-associated steatotic liver disease. Life Sci. 359, 123211 (2024).
Liu, A. N. et al. Secondary bile acids improve risk prediction for non-invasive identification of mild liver fibrosis in nonalcoholic fatty liver disease. Aliment Pharm. Ther. 57, 872–885 (2023).
Lin, H., An, Y., Tang, H. & Wang, Y. Alterations of bile acids and gut microbiota in obesity induced by high fat diet in rat model. J. Agric Food Chem. 67, 3624–3632 (2019).
Zhong, J. et al. Hyodeoxycholic acid ameliorates nonalcoholic fatty liver disease by inhibiting RAN-mediated PPARalpha nucleus-cytoplasm shuttling. Nat. Commun. 14, 5451 (2023).
Labiano, I. et al. TREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation. J. Hepatol. 77, 991–1004 (2022).
Huang, J. et al. Dynamic pattern of postprandial bile acids in paediatric non-alcoholic fatty liver disease. Liver Int. 44, 2793–2806 (2024).
Kuang, J. et al. Hyodeoxycholic acid alleviates non-alcoholic fatty liver disease through modulating the gut-liver axis. Cell Metab. 35, 1752–1766.e1758 (2023).
Wang, H. et al. Tauroursodeoxycholic acid improves nonalcoholic fatty liver disease by regulating gut microbiota and bile acid metabolism. J. Agric Food Chem. 72, 20194–20210 (2024).
La, X. et al. Isorhamnetin in quinoa whole-grain flavonoids intervenes in non-alcoholic fatty liver disease by modulating bile acid metabolism through regulation of FXR expression. Foods 13, 3076 (2024).
Badmus, O. O. et al. Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways. Clin. Sci.136, 1347–1366 (2022).
Wang, G. et al. Tumour extracellular vesicles and particles induce liver metabolic dysfunction. Nature 618, 374–382 (2023).
Zhuang, P. et al. Circulating fatty acids and risk of severe non-alcoholic fatty liver disease in the UK biobank: a prospective cohort of 116 223 individuals. Food Funct. 15, 10527–10538 (2024).
Ipsen, D. H., Lykkesfeldt, J. & Tveden-Nyborg, P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol. Life Sci. 75, 3313–3327 (2018).
Huang, Y., Qin, Y., Liao, L. & Lin, F. Familial chylomicronemia syndrome caused by compound heterozygous mutation of lipoprotein lipase gene: a case report and review of literature. Clin. Chim. Acta 537, 112–117 (2022).
Aller, R., Izaola, O., Primo, D. & de Luis, D. Cholesteryl ester transfer protein variant (RS1800777) with liver histology in non-alcoholic fatty liver disease patients. Ann. Nutr. Metab. 73, 265–270 (2018).
Schmidt, A. F. et al. PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study. Lancet Diab. Endocrinol. 5, 97–105 (2017).
Sun, Y. et al. Integrative plasma and fecal metabolomics identify functional metabolites in adenoma-colorectal cancer progression and as early diagnostic biomarkers. Cancer Cell 42, 1386–1400.e1388 (2024).
Axelrod, C. L. et al. Metabolomic fingerprints of medical therapy versus bariatric surgery in patients with obesity and type 2 diabetes: the STAMPEDE trial. Diab. Care 47, 2024–2032 (2024).
Gente, K. et al. Altered serum metabolome as an indicator of paraneoplasia or concomitant cancer in patients with rheumatic disease. Ann. Rheum. Dis. 83, 974–983 (2024).
Di’Narzo, A. F. et al. Integrative analysis of the inflammatory bowel disease serum metabolome improves our understanding of genetic etiology and points to novel putative therapeutic targets. Gastroenterology 162, 828–843.e811 (2022).
Souto-Carneiro, M. et al. Differences in the serum metabolome and lipidome identify potential biomarkers for seronegative rheumatoid arthritis versus psoriatic arthritis. Ann. Rheum. Dis. 79, 499–506 (2020).
Li, J. et al. Microbial and metabolic profiles unveil mutualistic microbe-microbe interaction in obesity-related colorectal cancer. Cell Rep. Med. 5, 101429 (2024).
Katsuki, S. et al. Nanoparticle-mediated delivery of pitavastatin inhibits atherosclerotic plaque destabilization/rupture in mice by regulating the recruitment of inflammatory monocytes. Circulation 129, 896–906 (2014).
Li, L. et al. Statins inhibit paclitaxel-induced PD-L1 expression and increase CD8+ T cytotoxicity for better prognosis in breast cancer. Int. J. Surg. 110, 4716–4726 (2024).
Shahbaz, S. K. et al. Regulatory T cells: possible mediators for the anti-inflammatory action of statins. Pharm. Res 149, 104469 (2019).
Rozo, C. et al. Targeting the RhoA-ROCK pathway to reverse T-cell dysfunction in SLE. Ann. Rheum. Dis. 76, 740–747 (2017).
Miao, Y. et al. The activation of PPARgamma enhances Treg responses through up-regulating CD36/CPT1-mediated fatty acid oxidation and subsequent N-glycan branching of TbetaRII/IL-2Ralpha. Cell Commun. Signal 20, 48 (2022).
Cipolletta, D. et al. PPAR-gamma is a major driver of the accumulation and phenotype of adipose tissue Treg cells. Nature 486, 549–553 (2012).
Bapat, S. P. et al. Obesity alters pathology and treatment response in inflammatory disease. Nature 604, 337–342 (2022).
Rosser, E. C. et al. Microbiota-derived metabolites suppress arthritis by amplifying aryl-hydrocarbon receptor activation in regulatory B cells. Cell Metab. 31, 837–851.e810 (2020).
Li, G. et al. Microbiota metabolite butyrate constrains neutrophil functions and ameliorates mucosal inflammation in inflammatory bowel disease. Gut Microbes 13, 1968257 (2021).
Schwarz, A., Philippsen, R. & Schwarz, T. Induction of regulatory T cells and correction of cytokine disbalance by short-chain fatty acids: implications for psoriasis therapy. J. Investig. Dermatol 141, 95–104.e102 (2021).
Dierge, E. et al. Peroxidation of n-3 and n-6 polyunsaturated fatty acids in the acidic tumor environment leads to ferroptosis-mediated anticancer effects. Cell Metab. 33, 1701–1715.e1705 (2021).
Cartier, A. & Hla, T. Sphingosine 1-phosphate: lipid signaling in pathology and therapy. Science 366, eaar5551 (2019).
Kunkel, G. T., Maceyka, M., Milstien, S. & Spiegel, S. Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat. Rev. Drug Discov. 12, 688–702 (2013).
Kataoka, H. et al. FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. Cell Mol. Immunol. 2, 439–448 (2005).
Bail, K. et al. Differential effects of FTY720 on the B cell compartment in a mouse model of multiple sclerosis. J. Neuroinflamm. 14, 148 (2017).
Paroni, M. et al. Recognition of viral and self-antigens by T(H)1 and T(H)1/T(H)17 central memory cells in patients with multiple sclerosis reveals distinct roles in immune surveillance and relapses. J. Allergy Clin. Immunol. 140, 797–808 (2017).
Danese, S., Furfaro, F. & Vetrano, S. Targeting S1P in inflammatory bowel disease: new avenues for modulating intestinal leukocyte migration. J. Crohns Colitis 12, S678–S686 (2018).
Bongartz, T. et al. Treatment of active psoriatic arthritis with the PPARgamma ligand pioglitazone: an open-label pilot study. Rheumatology 44, 126–129 (2005).
Li, X. F. et al. PPAR-gamma alleviates the inflammatory response in TNF-alpha-induced fibroblast-like synoviocytes by binding to p53 in rheumatoid arthritis. Acta Pharm. Sin. 44, 454–464 (2023).
Inzucchi, S. E. et al. Pioglitazone prevents diabetes in patients with insulin resistance and cerebrovascular disease. Diab. Care 39, 1684–1692 (2016).
Sharabi, A. & Tsokos, G. C. T cell metabolism: new insights in systemic lupus erythematosus pathogenesis and therapy. Nat. Rev. Rheumatol. 16, 100–112 (2020).
Feinstein, D. L. et al. Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. Ann. Neurol. 51, 694–702 (2002).
Finch, E. R. et al. Activation of PPARgamma by endogenous prostaglandin J(2) mediates the antileukemic effect of selenium in murine leukemia. Blood 129, 1802–1810 (2017).
Reichle, A. et al. Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma. Cancer 101, 2247–2256 (2004).
Chowdhury, P. S., Chamoto, K., Kumar, A. & Honjo, T. PPAR-induced fatty acid oxidation in T cells increases the number of tumor-reactive CD8(+) T cells and facilitates anti-PD-1 therapy. Cancer Immunol. Res. 6, 1375–1387 (2018).
Liu, A. et al. Statins: adverse reactions, oxidative stress and metabolic interactions. Pharm. Ther. 195, 54–84 (2019).
Youssef, S. et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420, 78–84 (2002).
Zhang, Y. et al. Atorvastatin combined with imipenem alleviates lung injury in sepsis by inhibiting neutrophil extracellular trap formation via the ERK/NOX2 signaling pathway. Free Radic. Biol. Med. 220, 179–191 (2024).
Neuhaus, O. et al. Statins as immunomodulators: comparison with interferon-beta 1b in MS. Neurology 59, 990–997 (2002).
de Oliveira, D. M. et al. Simvastatin ameliorates experimental autoimmune encephalomyelitis by inhibiting Th1/Th17 response and cellular infiltration. Inflammopharmacology 23, 343–354 (2015).
Sviridov, D., Mukhamedova, N. & Miller, Y. I. Lipid rafts as a therapeutic target. J. Lipid Res. 61, 687–695 (2020).
Jin, H. et al. Targeting lipid metabolism to overcome EMT-associated drug resistance via integrin beta3/FAK pathway and tumor-associated macrophage repolarization using legumain-activatable delivery. Theranostics 9, 265–278 (2019).
Azuma, R. W. et al. HMG-CoA reductase inhibitor attenuates experimental autoimmune myocarditis through inhibition of T cell activation. Cardiovasc. Res. 64, 412–420 (2004).
Sato, K. et al. Statins reduce endothelial cell apoptosis via inhibition of TRAIL expression on activated CD4 T cells in acute coronary syndrome. Atherosclerosis 213, 33–39 (2010).
Coimbra, M. et al. Liposomal pravastatin inhibits tumor growth by targeting cancer-related inflammation. J. Control Release 148, 303–310 (2010).
Iyer, M. R., Kundu, B. & Wood, C. M. Soluble epoxide hydrolase inhibitors: an overview and patent review from the last decade. Expert Opin. Ther. Pat. 32, 629–647 (2022).
Kim, H. S. et al. The arachidonic acid metabolite 11,12-epoxyeicosatrienoic acid alleviates pulmonary fibrosis. Exp. Mol. Med. 53, 864–874 (2021).
Ghosh, A. et al. An epoxide hydrolase inhibitor reduces neuroinflammation in a mouse model of Alzheimer’s disease. Sci. Transl. Med. 12 (2020).
Zhang, J. et al. Genetic deletion or pharmacological inhibition of soluble epoxide hydrolase attenuated particulate matter 2.5 exposure-mediated lung injury. J. Hazard Mater. 458, 131890 (2023).
Zhang, C. Y. et al. EETs alleviate alveolar epithelial cell senescence by inhibiting endoplasmic reticulum stress through the Trim25/Keap1/Nrf2 axis. Redox Biol. 63, 102765 (2023).
Gowler, P. R. W. et al. Clinical and preclinical evidence for roles of soluble epoxide hydrolase in osteoarthritis knee pain. Arthritis Rheumatol. 74, 623–633 (2022).
Zhang, J. et al. Macrophage inactivation by small molecule wedelolactone via targeting sEH for the treatment of LPS-induced acute lung injury. ACS Cent. Sci. 9, 440–456 (2023).
Hammock, B. D. et al. Movement to the clinic of soluble epoxide hydrolase inhibitor EC5026 as an analgesic for neuropathic pain and for use as a nonaddictive opioid alternative. J. Med Chem. 64, 1856–1872 (2021).
Du, F. et al. Structure-guided discovery of potent and oral soluble epoxide hydrolase inhibitors for the treatment of neuropathic pain. Acta Pharm. Sin. B 12, 1377–1389 (2022).
Leuti, A. et al. Bioactive lipids, inflammation and chronic diseases. Adv. Drug Deliv. Rev. 159, 133–169 (2020).
Duffney, P. F. et al. Key roles for lipid mediators in the adaptive immune response. J. Clin. Investig. 128, 2724–2731 (2018).
Alnouri, M. W. et al. SPMs exert anti-inflammatory and pro-resolving effects through positive allosteric modulation of the prostaglandin EP4 receptor. Proc. Natl. Acad. Sci. USA 121, e2407130121 (2024).
Julliard, W. A. et al. Specialized pro-resolving mediators as modulators of immune responses. Semin. Immunol. 59, 101605 (2022).
Chiurchiu, V. et al. Proresolving lipid mediators resolvin D1, resolvin D2, and maresin 1 are critical in modulating T cell responses. Sci. Transl. Med. 8, 353ra111 (2016).
Oner, F. et al. Resolvin E1 regulates Th17 function and T cell activation. Front. Immunol. 12, 637983 (2021).
Abdolmaleki, F. et al. Resolvins: emerging players in autoimmune and inflammatory diseases. Clin. Rev. Allergy Immunol. 58, 82–91 (2020).
Quiros, M. et al. Resolvin E1 is a pro-repair molecule that promotes intestinal epithelial wound healing. Proc. Natl. Acad. Sci. USA 117, 9477–9482 (2020).
Codagnone, M. et al. Resolvin D1 enhances the resolution of lung inflammation caused by long-term Pseudomonas aeruginosa infection. Mucosal Immunol. 11, 35–49 (2018).
Thompson, P. D., Panza, G., Zaleski, A. & Taylor, B. Statin-associated side effects. J. Am. Coll. Cardiol. 67, 2395–2410 (2016).
Collins, R. et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 388, 2532–2561 (2016).
Ward, N. C., Watts, G. F. & Eckel, R. H. Statin Toxicity. Circ. Res. 124, 328–350 (2019).
Jiang, W. et al. Statins: a repurposed drug to fight cancer. J. Exp. Clin. Cancer Res. 40, 241 (2021).
Wassif, C. A. et al. A placebo-controlled trial of simvastatin therapy in Smith-Lemli-Opitz syndrome. Genet Med. 19, 297–305 (2017).
Mikus, C. R. et al. Simvastatin impairs exercise training adaptations. J. Am. Coll. Cardiol. 62, 709–714 (2013).
Robinson, A. B. et al. Vitamin D status is a determinant of atorvastatin effect on carotid intima-medial thickening progression rate in children with lupus: an Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) substudy. Lupus Sci. Med. 1, e000037 (2014).
Garwood, E. R. et al. Fluvastatin reduces proliferation and increases apoptosis in women with high-grade breast cancer. Breast Cancer Res. Treat. 119, 137–144 (2010).
Erkan, D. et al. A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients. Ann. Rheum. Dis. 73, 1176–1180 (2014).
Ju, S. H. et al. Distinct effects of rosuvastatin and rosuvastatin/ezetimibe on senescence markers of CD8+ T cells in patients with type 2 diabetes mellitus: a randomized controlled trial. Front Endocrinol.15, 1336357 (2024).
Cho, Y. et al. Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study). BMC Med. 20, 93 (2022).
Moon, J. S. et al. The efficacy and safety of moderate-intensity rosuvastatin with ezetimibe versus high-intensity rosuvastatin in high atherosclerotic cardiovascular disease risk patients with type 2 diabetes mellitus: a randomized, multicenter, open, parallel, phase 4 study. Diab. Metab. J. 47, 818–825 (2023).
Yamashita, S., Masuda, D. & Matsuzawa, Y. Pemafibrate, a New Selective PPARalpha modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases. Curr. Atheroscler. Rep. 22, 5 (2020).
Emami, F., Hariri, A., Matinfar, M. & Nematbakhsh, M. Fenofibrate-induced renal dysfunction, yes or no?. J. Res. Med. Sci. 25, 39 (2020).
Michaeli, D. T. et al. Established and emerging lipid-lowering drugs for primary and secondary cardiovascular prevention. Am. J. Cardiovasc Drugs 23, 477–495 (2023).
Bansal, G. et al. An overview on medicinal perspective of thiazolidine-2,4-dione: A remarkable scaffold in the treatment of type 2 diabetes. J. Adv. Res. 23, 163–205 (2020).
Mal, S. et al. Role of peroxisome proliferator-activated receptor gamma (PPARgamma) in different disease states: recent updates. Curr. Med. Chem. 28, 3193–3215 (2021).
Singh, G. et al. Thiazolidinedione as a promising medicinal scaffold for the treatment of type 2 diabetes. Curr. Diab. Rev. 20, e201023222411 (2024).
Liu, Y. et al. Effectiveness of fenofibrate in treatment-naive patients with primary biliary cholangitis: a randomized clinical trial. Am. J. Gastroenterol. 118, 1973–1979 (2023).
Gilbert, K. et al. Fenofibrate lowers blood pressure in salt-sensitive but not salt-resistant hypertension. J. Hypertens. 31, 820–829 (2013).
Lawitz, E. J. et al. Fenofibrate mitigates hypertriglyceridemia in nonalcoholic steatohepatitis patients treated with cilofexor/firsocostat. Clin. Gastroenterol. Hepatol. 21, 143–152.e143 (2023).
Cusi, K. et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann. Intern. Med. 165, 305–315 (2016).
Sun, R. et al. Impact of fixed combination of metformin and pioglitazone on insulin resistance of patients with type 2 diabetes: results of a randomized open-label study. Diab. Metab. Syndr. Obes. 16, 2911–2919 (2023).
Investigators, N. E. T. i. P. D. F.-Z. Pioglitazone in early Parkinson’s disease: a phase 2, multicentre, double-blind, randomised trial. Lancet Neurol. 14, 795–803 (2015).
Kaler, M. et al. A randomized, placebo-controlled, double-blinded, crossover trial of pioglitazone for severe asthma. J. Allergy Clin. Immunol. 140, 1716–1718 (2017).
Park, J. Y. et al. Efficacy and safety of alogliptin-pioglitazone combination for type 2 diabetes mellitus poorly controlled with metformin: a multicenter, double-blind randomized trial. Diab. Metab. J. 48, 915–928 (2024).
Heo, J. H. et al. Pioglitazone as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled with dapagliflozin and metformin: double-blind, randomized, placebo-controlled trial. Diab. Metab. J. 48, 937–948 (2024).
Lim, S. et al. A multicentre, double-blind, placebo-controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add-on therapy in type 2 diabetic patients treated with metformin and dapagliflozin. Diab. Obes. Metab. 26, 2188–2198 (2024).
Goyal, N. P. et al. An open label, randomized, multicenter study of elafibranor in children with nonalcoholic steatohepatitis. J. Pediatr. Gastroenterol. Nutr. 77, 160–165 (2023).
Schattenberg, J. M. et al. A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. J. Hepatol. 74, 1344–1354 (2021).
Kowdley, K. V. et al. Efficacy and safety of elafibranor in primary biliary cholangitis. N. Engl. J. Med 390, 795–805 (2024).
de Wit-Verheggen, V. H. W. et al. The tissue-specific metabolic effects of the PPARalpha agonist ciprofibrate in insulin-resistant male individuals: a double-blind, randomized, placebo-controlled crossover study. Obesity31, 2493–2504 (2023).
Chevalier, L., Vachon, A. & Plourde, M. Pharmacokinetics of supplemental omega-3 fatty acids esterified in monoglycerides, ethyl esters, or triglycerides in adults in a randomized crossover trial. J. Nutr. 151, 1111–1118 (2021).
Metkus, T. S. et al. Omega-3 fatty acid therapy reduces triglycerides and interleukin-6 in hypertriglyeridemic HIV patients. HIV Med. 14, 530–539 (2013).
Luther, J. M. et al. GSK2256294 decreases sEH (soluble epoxide hydrolase) activity in plasma, muscle, and adipose and reduces F2-isoprostanes but does not alter insulin sensitivity in humans. Hypertension 78, 1092–1102 (2021).
Lazaar, A. L. et al. Pharmacokinetics, pharmacodynamics and adverse event profile of GSK2256294, a novel soluble epoxide hydrolase inhibitor. Br. J. Clin. Pharm. 81, 971–979 (2016).
Martini, R. P. et al. A double-blind, randomized, placebo-controlled trial of soluble epoxide hydrolase inhibition in patients with aneurysmal subarachnoid hemorrhage. Neurocrit. Care 36, 905–915 (2022).
Schmidt, W. K. et al. Randomized, double-blind, phase 1a single-ascending dose and food effect studies assessing safety and pharmacokinetics of EC5026 in healthy volunteers. Clin. Transl. Sci. 17, e70033 (2024).
van den Elsen, L. W. et al. Increased intake of vegetable oil rich in n-6 PUFA enhances allergic symptoms and prevents oral tolerance induction in whey-allergic mice. Br. J. Nutr. 114, 577–585 (2015).
Daniel, C. et al. FTY720 ameliorates Th1-mediated colitis in mice by directly affecting the functional activity of CD4+CD25+ regulatory T cells. J. Immunol. 178, 2458–2468 (2007).
Ng, T. W. et al. Association of plasma ceramides and sphingomyelin with VLDL apoB-100 fractional catabolic rate before and after rosuvastatin treatment. J. Clin. Endocrinol. Metab. 100, 2497–2501 (2015).
Daida, H. et al. High HbA1c levels correlate with reduced plaque regression during statin treatment in patients with stable coronary artery disease: results of the coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). Cardiovasc. Diabetol. 11, 87 (2012).
Thurm, A. et al. Development, behavior, and biomarker characterization of Smith-Lemli-Opitz syndrome: an update. J. Neurodev. Disord. 8, 12 (2016).
Kowalski, J. L. et al. miR-338-5p levels and cigarette smoking are associated with neuropathic pain severity in individuals with spinal cord injury: preliminary findings from a genome-wide microRNA expression profiling screen. Arch. Phys. Med. Rehabil. 103, 738–746 (2022).
Mohamed, H. Z., Sabri, N. A., Zaki, H. M. & Shaheen, S. M. Clinical effects of simvastatin in chronic hepatitis C patients receiving sofosbuvir/daclatasvir combination. A randomized, placebo-controlled, double-blinded study. Clin. Exp. Hepatol. 6, 99–105 (2020).
Singh, P. P. et al. Perioperative simvastatin therapy in major colorectal surgery: a prospective, double-blind randomized controlled trial. J. Am. Coll. Surg. 223, 308–320 e301 (2016).
Banaszewska, B. et al. Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. J. Clin. Endocrinol. Metab. 92, 456–461 (2007).
Zand, L. et al. Renal hemodynamic effects of the HMG-CoA reductase inhibitors in autosomal dominant polycystic kidney disease. Nephrol. Dial. Transpl. 31, 1290–1295 (2016).
Sparks, D. L. et al. Atorvastatin for the treatment of mild to moderate Alzheimer’s disease: preliminary results. Arch. Neurol. 62, 753–757 (2005).
Braganza, G. et al. Effects of short-term treatment with atorvastatin in smokers with asthma–a randomized controlled trial. BMC Pulm. Med. 11, 16 (2011).
Waubant, E. et al. Randomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS study. Neurology 78, 1171–1178 (2012).
Mandal, P. et al. Atorvastatin as a stable treatment in bronchiectasis: a randomised controlled trial. Lancet Respir. Med. 2, 455–463 (2014).
Antoniades, C. et al. Myocardial redox state predicts in-hospital clinical outcome after cardiac surgery, effects of short-term pre-operative statin treatment. J. Am. Coll. Cardiol. 59, 60–70 (2012).
Neilipovitz, D. T., Bryson, G. L. & Taljaard, M. STAR VaS–short term atorvastatin regime for vasculopathic subjects: a randomized placebo-controlled trial evaluating perioperative atorvastatin therapy in noncardiac surgery. Can. J. Anaesth. 59, 527–537 (2012).
Ostadal, P. et al. Fluvastatin in the first-line therapy of acute coronary syndrome: results of the multicenter, randomized, double-blind, placebo-controlled trial (the FACS-trial). Trials 11, 61 (2010).
Matsubara, T. et al. Impact of pitavastatin on high-sensitivity C-reactive protein and adiponectin in hypercholesterolemic patients with the metabolic syndrome: the PREMIUM Study. J. Cardiol. 60, 389–394 (2012).
Jeong, H. S. et al. Incidence of new-onset diabetes with 1 mg versus 4 mg pitavastatin in patients at high risk of developing diabetes during a 3-year follow-up. Cardiovasc. Diabetol. 18, 162 (2019).
Ose, L., Budinski, D., Hounslow, N. & Arneson, V. Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia. Atherosclerosis 210, 202–208 (2010).
Braun, L. R. et al. Effects of pitavastatin on insulin sensitivity and liver fat: a randomized clinical trial. J. Clin. Endocrinol. Metab. 103, 4176–4186 (2018).
Morieri, M. L. et al. PPARA polymorphism influences the cardiovascular benefit of fenofibrate in type 2 diabetes: findings from ACCORD-lipid. Diabetes 69, 771–783 (2020).
Pershadsingh, H. A. et al. Effect of pioglitazone treatment in a patient with secondary multiple sclerosis. J. Neuroinflamm. 1, 3 (2004).
Carta, A. R. & Simuni, T. Thiazolidinediones under preclinical and early clinical development for the treatment of Parkinson’s disease. Expert Opin. Investig. Drugs 24, 219–227 (2015).
Berhanu, P. et al. Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy. Diab Vasc. Dis. Res. 3, 39–44 (2006).
Szapary, P. O. et al. Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 26, 182–188 (2006).
Mai, K. et al. Rosiglitazone increases fatty acid Delta9-desaturation and decreases elongase activity index in human skeletal muscle in vivo. Metabolism 61, 108–116 (2012).
Kadoglou, N. P. et al. Beneficial effects of combined treatment with rosiglitazone and exercise on cardiovascular risk factors in patients with type 2 diabetes. Diab. Care 30, 2242–2244 (2007).
Savinova, O. V., Fillaus, K., Harris, W. S. & Shearer, G. C. Effects of niacin and omega-3 fatty acids on the apolipoproteins in overweight patients with elevated triglycerides and reduced HDL cholesterol. Atherosclerosis 240, 520–525 (2015).